Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

BioSpace – Sutro Biopharma Maximizes Synergy to Treat Cancer and Preserve Quality of Life

News

BioSpace – Sutro Biopharma Maximizes Synergy to Treat Cancer and Preserve Quality of Life https://www.biospace.com/article/sutro-maximizes-synergy-to-treat-cancer-and-preserve-quality-of-life/ By: Heather McKenzie Published: Jan. 12, 2021   Sutro Biopharma wants...

Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference

Events, News, Press Releases

Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application...

Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

News, Press Releases

Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters’ Option to Purchase Additional Shares South San Francisco, Calif., Dec. 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug...

Onco’Zine – ASH 2020: Preclinical Models Identify CD74 as Potential Target for the Treatment of AML

News

Onco’Zine – ASH 2020: Preclinical Models Identify CD74 as Potential Target for the Treatment of AML Peter Hofland, Ph.D. Dec 8, 2020 https://www.oncozine.com/ash-2020-preclinical-models-identifies-cd74-as-potential-target-for-the-treatment-of-aml/    Presentations...

Sutro Biopharma Announces Pricing of $126.0 Million Public Offering

News, Press Releases

Sutro Biopharma Announces Pricing of $126.0 Million Public Offering South San Francisco, Calif., Dec. 8, 2020 — Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...
« Older Entries
Next Entries »

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080

Phone: 650-881-6500

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2026 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY  | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

 

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.